Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunityinvestors.comAnalysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced.
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.investors.comBiotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approvalbenzinga.comBiohaven's BHV-1300 shows >60% IgG reduction in early trials with promising safety data, advancing its MoDE platform and regulatory milestones.
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry'benzinga.comArgenx SE ADR shares jumped after impressive earnings. Analysts raised price targets and noted strong pipeline and global expansion.
Biotech Stocks : Are You A Trader Or A Longer Term Investor?talkmarkets.comBiotech bull market is intact as indicated by large cap biopharma and the best performing funds.
